BioArctic AB Series B
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and other CNS diseases. In addition, … Read more
BioArctic AB Series B (0RV2) - Total Assets
Latest total assets as of December 2021: Skr897.73 Million SEK
Based on the latest financial reports, BioArctic AB Series B (0RV2) holds total assets worth Skr897.73 Million SEK as of December 2021.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
BioArctic AB Series B - Total Assets Trend (2017–2021)
This chart illustrates how BioArctic AB Series B’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
BioArctic AB Series B - Asset Composition Analysis
Current Asset Composition (December 2021)
BioArctic AB Series B's total assets of Skr897.73 Million consist of 96.0% current assets and 4.0% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 94.5% |
| Accounts Receivable | Skr9.04 Million | 1.0% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr33.75 Million | 3.8% |
| Intangible Assets | Skr0.00 | 0.0% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2017–2021)
This chart illustrates how BioArctic AB Series B's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BioArctic AB Series B's current assets represent 96.0% of total assets in 2021, a decrease from 99.1% in 2017.
- Cash Position: Cash and equivalents constituted 94.5% of total assets in 2021, down from 97.4% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is property, plant & equipment at 3.8% of total assets.
BioArctic AB Series B Competitors by Total Assets
Key competitors of BioArctic AB Series B based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
| No similar companies found. | ||
BioArctic AB Series B - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - BioArctic AB Series B generates 0.03x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - BioArctic AB Series B is currently not profitable relative to its asset base.
BioArctic AB Series B - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 11.59 | 8.31 | 9.27 |
| Quick Ratio | 11.59 | 8.31 | 9.27 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr964.21 Million | Skr 666.43 Million | Skr 899.64 Million |
BioArctic AB Series B - Advanced Valuation Insights
This section examines the relationship between BioArctic AB Series B's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.82 |
| Asset Growth Rate (YoY) | -14.5% |
| Total Assets | Skr897.73 Million |
| Market Capitalization | $734.10 Million USD |
Valuation Analysis
Near Book Valuation: The market values BioArctic AB Series B's assets close to their book value ( 0.82x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: BioArctic AB Series B's assets decreased by 14.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for BioArctic AB Series B (2017–2021)
The table below shows the annual total assets of BioArctic AB Series B from 2017 to 2021.
| Year | Total Assets | Change |
|---|---|---|
| 2021-12-31 | Skr897.73 Million | -14.53% |
| 2020-12-31 | Skr1.05 Billion | -11.24% |
| 2019-12-31 | Skr1.18 Billion | -15.05% |
| 2018-12-31 | Skr1.39 Billion | +22.14% |
| 2017-12-31 | Skr1.14 Billion | -- |